SCHEMBL6277569

SCHEMBL6277569

CC(=O)c1cc2c(c(Br)c1O)C(C)(C)CCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 2/20 0.40
RARB P10826 2/20 0.40
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
RXRG P48443 2/20 0.36
MEN1 O00255 3/20 0.30
MAPT P10636 3/20 0.30
KMT2A Q03164 3/20 0.30
KDM4E B2RXH2 2/20 0.30
NSD2 O96028 1/20 0.30
POLB P06746 1/20 0.30
MCL1 Q07820 1/20 0.30
BCL9 O00512 3/20 0.30
CTNNB1 P35222 3/20 0.30
ALDH1A1 P00352 2/20 0.30
CYP3A4 P08684 2/20 0.30
HPGD P15428 2/20 0.30
PTGES O14684 1/20 0.30
CYP2C9 P11712 1/20 0.30
FDPS P14324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281180 0.82 RXRA (0.34) RXRARXRBRXRGMAPTHSD17B10
SCHEMBL6514948 0.75
SCHEMBL31009036 0.74 NLRP3 (0.37) MEN1MAPTKMT2AKDM4ENSD2
SCHEMBL11444668 0.74 MEN1 (0.36) MEN1MAPTKMT2AKDM4ENSD2
SCHEMBL29258060 0.74 NLRP3 (0.37) MEN1MAPTKMT2AKDM4ENSD2
SCHEMBL6224438 0.72 RARA (0.34) RARARARB
SCHEMBL6281772 0.72 RXRA (0.50) RARARARBRXRARXRBRXRG
SCHEMBL34461266 0.69 AKT1 (0.37) RXRARXRBRXRGMEN1MAPT
SCHEMBL6279862 0.69 SIGMAR1 (0.31) RARACYP3A4CYP2C9
SCHEMBL6280922 0.66 GGPS1 (0.32) FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005042509-A1 7-`(7-ALKOXY)-CHROM-3-EN-6-YL!-HEPTATRIENOIC ACID AND 7-`(3­ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL!-HEPTATRIENOIC ACID DERIVATIVES MODULATORS ALLERGAN, INC. (US) 2005-05-12 WO disclosed
US-20050096380-A1 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY ALLERGAN, INC. 2005-05-05 US disclosed
US-6887896-B1 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity ALLERGAN, INC. (US) 2005-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096380-A1 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY TPO, THRA, FABP6 RARA 47/4885RARB 98/4885RXRA 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.